16750 Federal Register / Vol. 87, No. 57 / Thursday, March 24, 2022 / Notices 

60. Fahtima Isaac, Phoenix, Arizona, 

Court of Federal Claims No: 22– 

0213V 

61. Shannon McDonald, Lumberton, 

New Jersey, Court of Federal Claims 

No: 22–0215V 

62. Anita Enns, Katy, Texas, Court of 

Federal Claims No: 22–0216V 

63. Joyce Glenn on behalf of the Estate 

of Anthony Glenn, Deceased, 

Fontana, California, Court of 

Federal Claims No: 22–0217V 

64. April Keen, Greenville, South 

Carolina, Court of Federal Claims 

No: 22–0218V 

65. Carey Cribbs, Ferndale, Michigan, 

Court of Federal Claims No: 22– 

0219V 

66. Sara Davis Buechner, Philadelphia, 

Pennsylvania, Court of Federal 

Claims No: 22–0220V 

67. Rafael Mauries, Cedar Park, Texas, 

Court of Federal Claims No: 22– 

0224V 

[FR Doc. 2022–06249 Filed 3–23–22; 8:45 am] 

BILLING CODE 4165–15–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Meeting of the Tick-Borne Disease 

Working Group 

AGENCY: Office of the Assistant 

Secretary for Health, Office of the 

Secretary, Department of Health and 

Human Services. 

ACTION: Notice. 

SUMMARY: As required by the Federal 

Advisory Committee Act, the 

Department of Health and Human 

Services (HHS) is hereby giving notice 

that the Tick-Borne Disease Working 

Group (TBDWG) will hold a virtual 

meeting. The meeting will be open to 

the public. For this meeting, the 

TBDWG will be discussing and voting 

on recommendations for the 2022 

TBDWG Report to the HHS Secretary 

and Congress. Most of the 

recommendations the TBDWG will 

consider are from the reports of five 

TBDWG subcommittees, which were 

created to examine critical topic areas 

related to tick-borne diseases. The 2022 

report will address a wide range of 

topics related to tick-borne diseases, 

such as, surveillance, prevention, 

diagnosis, diagnostics, and treatment; 

identify advances made in research, as 

well as overlap and gaps in tick-borne 

disease research; and provide 

recommendations regarding any 

appropriate changes or improvements to 

such activities and research. 

DATES: The meeting will be held online 

via webcast on April 27, 2022–April 28, 

2022 from approximately 9:00 a.m. to 

5:00 p.m. ET (times are tentative and 

subject to change) each day. The 

confirmed times and agenda items for 

the meeting will be posted on the 

TBDWG web page https://www.hhs.gov/ 

ash/advisory-committees/tickborne

disease/meetings/2022-04-27/ 

index.html when this information 

becomes available. 

FOR FURTHER INFORMATION CONTACT: 

James Berger, Designated Federal Officer 

for the TBDWG; Office of Infectious 

Disease and HIV/AIDS Policy, Office of 

the Assistant Secretary for Health, 

Department of Health and Human 

Services, Mary E. Switzer Building, 330 

C Street SW, Suite L600, Washington, 

DC 20024. Email: tickbornedisease@

hhs.gov. Phone: 202–795–7608. 

SUPPLEMENTARY INFORMATION: 

Registration information can be found 

on the meeting website at https://

www.hhs.gov/ash/advisory-committees/ 

tickbornedisease/meetings/2022-04-27/ 

index.html when it becomes available. 

The public will have an opportunity to 

present their views to the TBDWG orally 

during the meeting’s public comment 

session or by submitting a written 

public comment. Comments should be 

pertinent to the meeting discussion. 

Persons who wish to provide verbal or 

written public comment should review 

instructions at https://www.hhs.gov/ 

ash/advisory-committees/tickborne

disease/meetings/2022-04-27/ 

index.html and respond by midnight 

April 15, 2022 ET. Verbal comments 

will be limited to three minutes each to 

accommodate as many speakers as 

possible during the 30 minute session. 

Written public comments will be 

accessible to the public on the TBDWG 

web page prior to the meeting. 

Background and Authority: The TickBorne Disease Working Group was 

established on August 10, 2017, in 

accordance with Section 2062 of the 

21st Century Cures Act, and the Federal 

Advisory Committee Act, 5 U.S.C. App., 

as amended, to provide expertise and 

review federal efforts related to all tickborne diseases, to help ensure 

interagency coordination and minimize 

overlap, and to examine research 

priorities. The TBDWG is required to 

submit a report to the HHS Secretary 

and Congress on their findings and any 

recommendations for the federal 

response to tick-borne disease every two 

years. 

Dated: March 14, 2022. 

James J. Berger, 

Designated Federal Officer, Tick-Borne 

Disease Working Group, Office of Infectious 

Disease and HIV/AIDS Policy. 

[FR Doc. 2022–06226 Filed 3–23–22; 8:45 am] 

BILLING CODE 4150–28–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Office of the Secretary 

Findings of Research Misconduct 

AGENCY: Office of the Secretary, HHS. 

ACTION: Notice. 

SUMMARY: Findings of research 

misconduct have been made against Hui 

(Herb) Bin Sun, Ph.D. (Respondent), 

formerly Professor of Orthopedic 

Surgery and Radiation Oncology, Albert 

Einstein College of Medicine (AECM). 

Respondent engaged in research 

misconduct in research supported by 

U.S. Public Health Service (PHS) funds, 

specifically National Institute of 

Arthritis and Musculoskeletal and Skin 

Diseases (NIAMS), National Institutes of 

Health (NIH), grant R01 AR050968 and 

National Heart, Lung, and Blood 

Institute (NHLBI), NIH, grant P01 

HL110900. The administrative actions, 

including supervision for a period of 

twelve (12) years, were implemented 

beginning on March 1, 2022, and are 

detailed below. 

FOR FURTHER INFORMATION CONTACT: 

Wanda K. Jones, Dr.P.H., Acting 

Director, Office of Research Integrity, 

1101 Wootton Parkway, Suite 240, 

Rockville, MD 20852, (240) 453–8200. 

SUPPLEMENTARY INFORMATION: Notice is 

hereby given that the Office of Research 

Integrity (ORI) has taken final action in 

the following case: 

Hui (Herb) Bin Sun, Ph.D., Albert 

Einstein College of Medicine: Based on 

the report of an investigation conducted 

by AECM and analysis conducted by 

ORI in its oversight review, ORI found 

that Dr. Sun, formerly Professor of 

Orthopedic Surgery and Radiation 

Oncology, AECM, engaged in research 

misconduct in research supported by 

PHS funds, specifically NIAMS, NIH, 

grant R01 AR050968 and NHLBI, NIH, 

grant P01 HL110900. 

ORI found that Respondent engaged 

in research misconduct by intentionally, 

knowingly, or recklessly falsifying and/ 

or fabricating data included in sixteen 

(16) grant applications submitted for 

PHS funds: 

• R01 AR065563–01, ‘‘CITED2 and 

Chondroprotection,’’ submitted to 

NIAMS, NIH, on 02/05/2013. 


khammond on DSKJM1Z7X2PROD with NOTICES